Olezarsen for Managing Severe Hypertriglyceridemia and Pancreatitis Risk.

Summary

Two double-blind RCTs (n=1061) show that monthly olezarsen (50 or 80 mg) reduces triglycerides by roughly 50–72 percentage points vs. placebo at 6 months and lowers acute pancreatitis incidence (rate ratio 0.15). Safety was generally similar, though liver enzyme elevations, thrombocytopenia, and dose-dependent hepatic fat increase were more frequent at 80 mg.

Key Findings

• At 6 months, placebo-adjusted TG reductions ranged from −49.2 to −72.2 percentage points across trials and doses (P<0.001).
• Acute pancreatitis incidence was significantly lower with olezarsen (mean rate ratio 0.15, 95% CI 0.05–0.40).
• Greater reductions in APOC3, remnant cholesterol, and non-HDL cholesterol vs. placebo.
• Adverse events overall were similar, but liver enzyme elevations, thrombocytopenia, and a dose-dependent hepatic fat increase were more frequent at 80 mg.

Clinical Implications

Olezarsen offers a potent option to reduce triglycerides and pancreatitis risk in severe hypertriglyceridemia. Clinicians should monitor liver enzymes, platelets, and hepatic fat, especially with higher doses, and consider patient selection for maximal benefit.

Limitations

• Increased liver enzymes, thrombocytopenia, and hepatic fat with higher dose raise safety monitoring needs
• Primary outcome focused on lipid change at 6 months; longer-term safety and outcomes beyond 12 months require confirmation

Future Directions

Evaluate long-term clinical outcomes, optimize dosing to balance efficacy and safety, and assess use in pancreatitis-prone subgroups and in combination with other lipid-lowering agents.